STOCK TITAN

Zentalis Pharmaceuticals, Inc. - ZNTL STOCK NEWS

Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.

The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.

Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.

The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.

Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.

Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.

Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) is hosting a virtual R&D Day on December 16, 2021, from 11:00 a.m. to 12:00 p.m. EST. The event will feature management and three Key Opinion Leaders discussing preclinical science and clinical updates on pipeline candidates, including ZN-d5, an oral BCL-2 inhibitor, and ZN-e4, an oral EGFR inhibitor. Registration is available on their website. Zentalis specializes in developing small molecule therapeutics targeting cancer-related biological pathways.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
conferences
-
Rhea-AI Summary

Zentalis Pharmaceuticals announces the FDA has granted Fast Track designation for its oral WEE1 inhibitor candidate, ZN-c3, aimed at treating recurrent uterine serous carcinoma (USC). This development is significant due to the aggressive nature of USC and its high recurrence rates, underscoring the urgent need for effective therapies. ZN-c3 is currently in a potential registrational Phase 2 trial, with safety updates expected in the second half of 2022. Fast Track designation allows for streamlined communication with the FDA, potentially expediting the approval process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported financial results for Q3 2021, revealing a net loss of $10.5 million, significantly lower than the $34.7 million loss in Q3 2020. The company initiated a Phase 1/2 trial for ZN-c3 combined with gemcitabine in osteosarcoma and is progressing in a Phase 2 trial for uterine serous carcinoma. As of September 30, 2021, Zentalis holds $366.8 million in cash, expected to sustain operations through Q3 2023. Research and development expenses increased to $54 million, reflecting enhanced clinical activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
Rhea-AI Summary

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced that CEO Anthony Sun will present at two upcoming investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, at 8:40 a.m. EST, while the Jefferies London Healthcare Conference will be available on-demand starting November 18, 2021, at 8:00 a.m. GMT. Webcasts for these presentations will be accessible via the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences
-
Rhea-AI Summary

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has initiated a Phase 1/2 trial for ZN-c3, an oral WEE1 inhibitor, in combination with gemcitabine for treating relapsed or refractory osteosarcoma. The trial aims to evaluate clinical safety and efficacy, with initial results expected in the second half of 2022. Zentalis has received orphan drug and rare pediatric disease designations from the FDA for this indication, potentially leading to a priority voucher upon approval. Osteosarcoma, primarily affecting younger patients, has a poor prognosis, highlighting the urgent need for effective therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
-
Rhea-AI Summary

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced the acceptance of six abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place virtually from September 16-21, 2021. Highlights include studies on ZN-c3, a WEE1 inhibitor, and ZN-c5, an oral selective estrogen receptor degrader, targeting advanced cancers. The posters will be accessible on the Congress platform starting September 16 at 8:30 a.m. CEST and will also appear on Zentalis' website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
Rhea-AI Summary

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced participation in two virtual investor conferences. The Morgan Stanley Global Healthcare Conference is on September 10, 2021, at 2:45 p.m. EDT, featuring a live fireside chat with CEO Anthony Sun. The H.C. Wainwright Global Life Sciences Conference follows on September 13, 2021, at 7:00 a.m. EDT, presented on demand. Webcasts will be available on the company’s website, showcasing Zentalis's focus on developing small molecule therapeutics for cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
-
Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the publication of its WEE1 inhibitor candidate, ZN-c3, in the Journal of Medicinal Chemistry. This selective WEE1 inhibitor aims to enhance cancer treatment efficacy by targeting the cell cycle regulator WEE1. ZN-c3 is under evaluation in multiple trials, including potential accelerated approval routes for uterine serous carcinoma. The company believes ZN-c3's profile may represent a best-in-class oncology treatment, following promising clinical results reported in June.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Summary

Zentalis Pharmaceuticals (ZNTL) reported promising new data for ZN-c3 and ZN-c5, highlighting their potential as best-in-class cancer therapies. The company successfully dosed the first patient in a Phase 2 trial for ZN-c3 targeting uterine serous carcinoma (USC). Additionally, Zentalis raised approximately $173 million in a public offering to support future milestones. The second quarter of 2021 saw a net loss of $55.1 million, driven by increased R&D expenses. As of June 30, 2021, Zentalis held $250.9 million in cash, which is expected to fund operations well into Q3 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Anthony Sun will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 10:20 a.m. ET. The event will be accessible via a live webcast on the company’s website. Zentalis focuses on developing small molecule therapeutics for cancer, with a pipeline including candidates like ZN-c3 and ZN-c5 targeting various tumors. The company operates in New York and San Diego.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences

FAQ

What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?

The current stock price of Zentalis Pharmaceuticals (ZNTL) is $3 as of December 20, 2024.

What is the market cap of Zentalis Pharmaceuticals (ZNTL)?

The market cap of Zentalis Pharmaceuticals (ZNTL) is approximately 217.4M.

What products is Zentalis Pharmaceuticals currently developing?

Zentalis is developing ZN-c5 for advanced ER+/HER2- breast cancer and ZN-c3 (azenosertib) for advanced solid tumors including ovarian cancer.

What is the purpose of Zentalis Pharmaceuticals' recent financial offering?

The company plans to use the proceeds to fund clinical trials, working capital, and general corporate purposes, ensuring operational stability through 2026.

What is azenosertib and why is it significant?

Azenosertib (ZN-c3) is a WEE1 inhibitor showing promising clinical data for treating ovarian cancer and uterine serous carcinoma as both a monotherapy and in combination with chemotherapy.

Where are Zentalis Pharmaceuticals' main operations located?

Zentalis Pharmaceuticals operates primarily out of New York and San Diego.

Who are Zentalis Pharmaceuticals' financial collaborators?

Morgan Stanley, Jefferies, SVB Securities, and Guggenheim Securities are among the financial institutions collaborating with Zentalis.

What is Zentalis’ Integrated Discovery Engine?

Zentalis' Integrated Discovery Engine is a proprietary drug discovery platform used to identify unique targets and develop novel small molecule therapeutics for cancer.

When does Zentalis plan to submit its first NDA for azenosertib?

Zentalis aims to submit its first NDA for azenosertib in gynecologic malignancies by 2026.

What are the recent clinical achievements of Zentalis Pharmaceuticals?

Zentalis has shown significant clinical data for azenosertib, particularly its effectiveness in treating ovarian cancer and uterine serous carcinoma.

How does Zentalis plan to use its expertise in cancer biology?

Zentalis leverages its expertise to advance research on protein degraders and explore innovative treatment modalities for cancer.

Where can one access more information about Zentalis Pharmaceuticals?

For more information, visit the Zentalis official website or follow them on social media platforms like Twitter and LinkedIn.

Zentalis Pharmaceuticals, Inc.

Nasdaq:ZNTL

ZNTL Rankings

ZNTL Stock Data

217.36M
64.53M
3.83%
98.06%
6.97%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO